Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update

Onconetix, Inc. (NASDAQ:ONCO) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 33,300 shares, a growth of 53.5% from the October 31st total of 21,700 shares. Currently, 1.0% of the company’s stock are sold short. Based on an average daily volume of 674,800 shares, the short-interest ratio is currently 0.0 days.

Hedge Funds Weigh In On Onconetix

An institutional investor recently bought a new position in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Onconetix, Inc. (NASDAQ:ONCO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 306,079 shares of the company’s stock, valued at approximately $51,000. Zurcher Kantonalbank Zurich Cantonalbank owned 1.37% of Onconetix at the end of the most recent quarter. Institutional investors and hedge funds own 23.89% of the company’s stock.

Onconetix Stock Performance

ONCO traded up $0.03 during midday trading on Friday, reaching $0.69. 940,428 shares of the company were exchanged, compared to its average volume of 318,680. The company’s fifty day moving average price is $3.35 and its 200 day moving average price is $5.16. Onconetix has a one year low of $0.60 and a one year high of $21.40.

Onconetix (NASDAQ:ONCO) last issued its quarterly earnings data on Thursday, August 29th. The company reported ($9.20) EPS for the quarter. The business had revenue of $0.71 million during the quarter.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.